JO3578B1 - تركيبة صيدلانية تحتوي على حمض النيكوتينيك و / أو النيكوتيناميد و / أو التربتوفان لإحداث تأثير إيجابي على الوسط البكتيري الموجود في الامعاء - Google Patents

تركيبة صيدلانية تحتوي على حمض النيكوتينيك و / أو النيكوتيناميد و / أو التربتوفان لإحداث تأثير إيجابي على الوسط البكتيري الموجود في الامعاء

Info

Publication number
JO3578B1
JO3578B1 JOP/2013/0182A JOP20130182A JO3578B1 JO 3578 B1 JO3578 B1 JO 3578B1 JO P20130182 A JOP20130182 A JO P20130182A JO 3578 B1 JO3578 B1 JO 3578B1
Authority
JO
Jordan
Prior art keywords
pharmaceutical composition
nicotinamide
tryptophan
composition containing
nicotinic acid
Prior art date
Application number
JOP/2013/0182A
Other languages
English (en)
Inventor
Seegert Dirk
Waetzig Georg
Original Assignee
Conaris Res Institute Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Conaris Res Institute Ag filed Critical Conaris Res Institute Ag
Application granted granted Critical
Publication of JO3578B1 publication Critical patent/JO3578B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

<span dir="RTL">يتعلق الاختراع الحالي بتركيبة صيدلانية جديدة تحتوي على حمض النيكوتينيك أو النيكوتيناميد أو التربتوفان أو المركبات ذات الصلة للتأثير إيجابياً على الجراثيم المعوية. في نماذج معينة ، يتم تحرير التركيبة الصيدلانية جزئيًا أو كليًا في الأمعاء الدقيقة أو الأمعاء الغليظة</span><span dir="RTL">.</span>
JOP/2013/0182A 2012-06-15 2013-06-16 تركيبة صيدلانية تحتوي على حمض النيكوتينيك و / أو النيكوتيناميد و / أو التربتوفان لإحداث تأثير إيجابي على الوسط البكتيري الموجود في الامعاء JO3578B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102012011890 2012-06-15

Publications (1)

Publication Number Publication Date
JO3578B1 true JO3578B1 (ar) 2020-07-05

Family

ID=47002494

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2013/0182A JO3578B1 (ar) 2012-06-15 2013-06-16 تركيبة صيدلانية تحتوي على حمض النيكوتينيك و / أو النيكوتيناميد و / أو التربتوفان لإحداث تأثير إيجابي على الوسط البكتيري الموجود في الامعاء

Country Status (32)

Country Link
US (2) US10426765B2 (ar)
EP (2) EP3831379A1 (ar)
JP (3) JP6855165B2 (ar)
KR (2) KR102211832B1 (ar)
CN (2) CN104363907A (ar)
AR (1) AR091465A1 (ar)
AU (1) AU2013276451B2 (ar)
BR (1) BR112014030835B1 (ar)
CA (1) CA2876540C (ar)
CY (1) CY1123999T1 (ar)
DK (1) DK2861229T3 (ar)
ES (1) ES2859758T3 (ar)
HK (1) HK1204972A1 (ar)
HR (1) HRP20210090T1 (ar)
HU (1) HUE053359T2 (ar)
IL (1) IL236205B (ar)
IN (1) IN2014DN10260A (ar)
JO (1) JO3578B1 (ar)
LT (1) LT2861229T (ar)
MX (1) MX370795B (ar)
NZ (1) NZ702297A (ar)
PH (1) PH12014502744A1 (ar)
PL (1) PL2861229T3 (ar)
PT (1) PT2861229T (ar)
RS (1) RS61288B1 (ar)
RU (1) RU2657797C2 (ar)
SA (1) SA113340643B1 (ar)
SG (1) SG11201408251SA (ar)
SI (1) SI2861229T1 (ar)
TW (1) TWI624260B (ar)
WO (1) WO2013186355A1 (ar)
ZA (1) ZA201408922B (ar)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2657797C2 (ru) 2012-06-15 2018-06-15 Конарис Рисерч Инститьют Аг Фармацевтическая композиция, содержащая никотиновую кислоту и/или никотинамид, и/или триптофан, для положительного воздействия на кишечную микробиоту
CA2914261C (en) 2013-06-05 2020-02-11 The University Of British Columbia Anti-fibrogenic compounds, methods and uses thereof
US10456389B2 (en) * 2013-06-14 2019-10-29 Conaris Research Institute Ag Extended release nicotinamide formulation
US10888555B2 (en) 2013-12-13 2021-01-12 Conaris Research Institute Ag Pharmaceutical composition containing nicotinic acid and/or nicotinamide for beneficially influencing blood lipid levels by modifying the intestinal microbiota
AU2014363430A1 (en) 2013-12-13 2016-06-16 Conaris Research Institute Ag A pharmaceutical composition containing combinations of nicotinamide and 5-aminosalicylic acid for beneficially influencing the intestinal microbiota and/or treating gastrointestinal inflammation
EP2884282A1 (en) 2013-12-13 2015-06-17 CONARIS research institute AG Use of tryptophan as a biomarker for patient selection, dosing and therapy monitoring for pharmaceutical compositions targeting the intestinal microbiota in diseases featuring tryptophan deficiency
WO2015124637A1 (en) * 2014-02-18 2015-08-27 Conaris Research Institute Ag Methods and compositions for intestinal microenvironment transfer
BR112016024400A2 (pt) * 2014-05-12 2017-08-15 Unilever Nv uso de niacinamida, niacinamida e método para melhorar a proteção do couro cabeludo
CN105287561A (zh) * 2015-11-25 2016-02-03 上海交通大学医学院附属瑞金医院 一种治疗溃疡性结肠炎的药物组合物
CA3021022C (en) * 2016-04-14 2024-04-23 ChromaDex Inc. Use of nicotinamide riboside, nicotinic acid riboside, nicotinamide mononucleotide, and nicotinoyl compound derivatives in infant formula
BR112018071363A2 (pt) * 2016-04-19 2019-02-05 Ferring Bv composições farmacêuticas orais de nicotinamida
TW201740932A (zh) 2016-04-19 2017-12-01 菲林公司 美沙拉 的口服醫藥組成物
CN109718234A (zh) * 2017-10-31 2019-05-07 中国农业大学 L-色氨酸在缓解肠道炎症反应和屏障功能紊乱中的应用
CN108935981A (zh) * 2018-06-05 2018-12-07 西北农林科技大学 围产期奶山羊添加烟酰胺对羔羊糖脂代谢的影响及其机制
CN113438896A (zh) * 2019-02-12 2021-09-24 田中惠 婴幼儿食品或饮料、用于改善婴幼儿肠道环境的方法和用于增强婴幼儿免疫力的方法
CN113573777A (zh) * 2019-03-28 2021-10-29 国立大学法人东北大学 癌的预防或治疗剂
CN113398130A (zh) * 2020-03-16 2021-09-17 广州市妇女儿童医疗中心（广州市妇幼保健院、广州市儿童医院、广州市妇婴医院、广州市妇幼保健计划生育服务中心） 烟酰胺用于预防和治疗胃肠道功能紊乱的用途
WO2022112489A1 (en) * 2020-11-27 2022-06-02 Conaris Research Institute Ag Nicotinamide, nicotinamide precursors and nicotinamide metabolites and compositions thereof for reducing the time to resolution of symptoms in patients with covid-19 and other viral infections
JPWO2023002939A1 (ar) * 2021-07-19 2023-01-26
WO2023187003A1 (en) * 2022-03-30 2023-10-05 Conaris Research Institute Ag Composition comprising nicotinamide, nicotinamide precursors, nicotinamide metabolites or combinations thereof for preventing or reducing one or more post-acute symptoms of infectious diseases

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6129930A (en) 1993-09-20 2000-10-10 Bova; David J. Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night
DE19524928A1 (de) * 1995-07-08 1997-01-09 Basf Ag Verfahren zur Rektifikation von Gemischen hochsiedender luft- und/oder temperaturempfindlicher Substanzen, die eine hohe Trennleistung erfordern, im Feinvakuum, sowie für dieses Verfahren geeignete Kolonnen
US5846983A (en) * 1996-02-09 1998-12-08 Mayo Foundation For Medical Education And Research Colonic delivery of nicotine to treat inflammatory bowel disease
US5736532A (en) * 1996-02-14 1998-04-07 Furda; Ivan Multifunctional fat absorption and blood cholesterol reducing formulation comprising chitosan
GB9614902D0 (en) * 1996-07-16 1996-09-04 Rhodes John Sustained release composition
BR9916567A (pt) * 1998-12-23 2001-12-11 Searle Llc Combinações de inibidores do transporte ácido dabile ileal e derivados do ácido nicotìnico paraindicações cardiovasculares
US6713057B1 (en) 1999-02-24 2004-03-30 The Johns Hopkins University Compositions and methods for modulating serum cholesterol
GB0015242D0 (en) 2000-06-22 2000-08-16 Nycomed Amersham Plc Stabiliser for radiopharmaceuticals
AU2001278699A1 (en) * 2000-08-08 2002-02-18 Shionogi And Co., Ltd. Inflammatory cytokine production inhibitors
US20040185097A1 (en) 2003-01-31 2004-09-23 Glenmark Pharmaceuticals Ltd. Controlled release modifying complex and pharmaceutical compositions thereof
US20060264409A1 (en) 2004-01-20 2006-11-23 Harty Richard F Compositions and methods of treatment for inflammatory diseases
EP1722630A4 (en) 2004-01-20 2009-05-27 Richard F Harty COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY DISEASES
WO2005115075A2 (en) 2004-05-27 2005-12-08 Antibe Therapeutics Inc. Salt of 4- or 5- aminosalicylic acid
EP2153824A1 (en) * 2004-09-27 2010-02-17 Sigmoid Pharma Limited Seamless multiparticulate formulations
EP1920770A4 (en) * 2005-07-01 2010-09-29 Ajinomoto Kk THERAPEUTIC AGENT AGAINST INFLAMMATORY DISEASE AND TNF ALPHA PRODUCTION DISEASE
CA2657606A1 (en) * 2006-03-08 2007-09-13 Cortria Corporation Combination therapy with non-selective cox inhibitors to prevent cox-related gastric injuries
ITMI20061932A1 (it) 2006-10-09 2008-04-10 Carlo Ghisalberti Complessi a trasferimento di carica per uso medicale
EP1935422A1 (en) * 2006-12-20 2008-06-25 PEJO Iserlohn Heilmittel-und Diät-GmbH & Co.KG Pharmaceutical composition comprising nicotinamide or nicotinic acid
WO2009051609A1 (en) * 2007-10-19 2009-04-23 Pardee Joel D Metabolic enhancement therapy
EP2276491A4 (en) * 2008-04-25 2011-08-17 Karolinska Inst Innovations Ab NEW THERAPY FOR THE TREATMENT OF IRRITATION SYNDROME
US20100015220A1 (en) * 2008-05-20 2010-01-21 Wetterau John R Niacin and nsaid combination therapy
TR201009949T1 (tr) 2008-06-02 2011-03-21 Dr. Reddy's Laboratories, Ltd. Salımı değiştirilmiş niasin formülasyonları.
WO2010040021A1 (en) 2008-10-03 2010-04-08 Salix Pharmaceuticals, Ltd. Compositions and methods for the treatment of bowel diseases with granulated mesalamine
JP2011121889A (ja) 2009-12-09 2011-06-23 En Otsuka Pharmaceutical Co Ltd 炎症性腸疾患用アミノ酸組成物
JP2012102054A (ja) * 2010-11-11 2012-05-31 Kyodo Milk Industry Co Ltd 腸内ポリアミン増強剤
WO2012090224A1 (en) 2010-12-29 2012-07-05 Nutracryst Therapeutics Private Limited Novel cocrystals / molecular salts of mesalamine to be used as improved anti-inflammatory drug
RU2657797C2 (ru) 2012-06-15 2018-06-15 Конарис Рисерч Инститьют Аг Фармацевтическая композиция, содержащая никотиновую кислоту и/или никотинамид, и/или триптофан, для положительного воздействия на кишечную микробиоту
US10456389B2 (en) 2013-06-14 2019-10-29 Conaris Research Institute Ag Extended release nicotinamide formulation
BR112018071363A2 (pt) 2016-04-19 2019-02-05 Ferring Bv composições farmacêuticas orais de nicotinamida

Also Published As

Publication number Publication date
BR112014030835A2 (pt) 2017-06-27
NZ702297A (en) 2016-11-25
TW201400116A (zh) 2014-01-01
DK2861229T3 (da) 2021-01-18
PL2861229T3 (pl) 2021-08-09
EP3831379A1 (en) 2021-06-09
CY1123999T1 (el) 2022-05-27
HUE053359T2 (hu) 2021-06-28
CN104363907A (zh) 2015-02-18
CA2876540C (en) 2022-11-29
IL236205B (en) 2020-02-27
IN2014DN10260A (ar) 2015-08-07
RS61288B1 (sr) 2021-02-26
HK1204972A1 (en) 2015-12-11
JP2019069972A (ja) 2019-05-09
US20150126462A1 (en) 2015-05-07
RU2014148239A (ru) 2016-08-10
US10426765B2 (en) 2019-10-01
JP2022017332A (ja) 2022-01-25
MX370795B (es) 2020-01-08
AR091465A1 (es) 2015-02-04
EP2861229A1 (en) 2015-04-22
JP2015519388A (ja) 2015-07-09
CA2876540A1 (en) 2013-12-19
AU2013276451A1 (en) 2015-01-15
KR20200011619A (ko) 2020-02-03
ZA201408922B (en) 2016-10-26
US20200009124A1 (en) 2020-01-09
LT2861229T (lt) 2021-01-25
ES2859758T3 (es) 2021-10-04
EP2861229B1 (en) 2020-12-23
HRP20210090T1 (hr) 2021-03-05
MX2014015217A (es) 2015-03-05
RU2657797C2 (ru) 2018-06-15
PH12014502744A1 (en) 2015-02-02
JP6855165B2 (ja) 2021-04-07
TWI624260B (zh) 2018-05-21
BR112014030835B1 (pt) 2022-01-11
IL236205A0 (en) 2015-01-29
SA113340643B1 (ar) 2019-10-06
AU2013276451B2 (en) 2018-03-29
CN108273064A (zh) 2018-07-13
PT2861229T (pt) 2021-01-05
WO2013186355A1 (en) 2013-12-19
SG11201408251SA (en) 2015-01-29
KR20150021071A (ko) 2015-02-27
KR102211832B1 (ko) 2021-02-02
SI2861229T1 (sl) 2021-03-31

Similar Documents

Publication Publication Date Title
PH12014502744A1 (en) A pharmaceutical composition containing nicotinic acid and/or nicotinamide and/or tryptophan for positively influencing the intestinal microbiota
GB201106743D0 (en) Novel compounds
WO2015086843A3 (en) A pharmaceutical composition containing nicotinic acid and/or nicotinamide for beneficially influencing blood lipid levels by modifying the intestinal microbiota
MY182428A (en) Crystalline forms of a prolyl hydroxylase inhibitor
IL233200A0 (en) The history of alpha-boronic acid, its preparation and pharmaceutical preparations containing it
GB201106750D0 (en) Novel compounds
PT2940014T (pt) Derivado 2,3-di-hidro-isoindol-1-ona como supressor da quinase btk e composição farmacêutica incluindo o mesmo
PH12016501059A1 (en) A pharmaceutical composition containing combinations of nicotinamide and 5-aminosalicylic acid for beneficially influencing the intestinal microbiota and/or treating gastrointestinal inflammation
MX357284B (es) Compuestos de quinona para tratar enfermedades mediadas por ape1.
IL235955A0 (en) The history of benzothiophene, their preparation and pharmaceutical preparations containing them
MX2015003034A (es) Jeringa que contiene una composicion, en particular farmaceutica, que comprende inmunoglobulinas, su metodo de fabricacion y uso.
MX355719B (es) Composicion farmaceutica en forma de una suspension oral que comprende una fraccion flavonoica y goma de xantano.
TN2015000095A1 (en) Macrolide derivatives, preparation thereof and therapeutic use thereof
EP2896625A4 (en) CO-CRYSTAL OF PIPÉRACILLIN SODIUM AND SULBACTAM SODIUM AND PROCESS FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AND USES THEREOF
IN2014DN07897A (ar)
IN2013CH04314A (ar)
MX351994B (es) Formas cristalinas de [(s)-1-carbamoil-2-(feniil-pirimidin-2-il-am ino)-etil]-amida del acido 2-(2-metilamino-pirimidin-4-il)-1h-indo l-5-carboxilico.
IN2014DN10683A (ar)
GEP201706747B (en) Pharmaceutical composition for reducing the trimethylamine n-oxide level
TH1401007439A (th) องค์ประกอบทางเภสัชกรรมที่มีนิโคตินิกแอซิด และ/หรือ นิโคตินาไมด์ และ/หรือ ทริปโตฟานเพื่อการมีอิทธิพลในด้านบวกต่อจุลชีพประจำถิ่นในลำไส้